Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-Term Safety and Efficacy of Povorcitinib in Hidradenitis Suppurativa
jRCT2051240088Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of povorcitinib in hidradenitis suppurativa (HS) (3 cohorts), sponsored by Incyte. Started Sep 2024; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2051240088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240088.